Dermatology Handbook

The professional's guide to product selection

Apremilast (Otezla)

Amgen

Description

Apremilast, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-α , IL-23, IL-17 and other inflammatory cytokines.

Indications

Otezla is indicated for the treatment of moderate to severe chronic plaque psoriasis, and arthritis psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).

Price

Otezla® Titration pack x 14 day = £265.18* Otezla® 30mg x 56 tablets = £550.00

More on: Systemic psoriasis treatments